A phase II, randomised, double-blind, placebo-controlled clinical trial to assess the safety and efficacy of AZD1656 in patients with diabetes hospitalised with suspected or confirmed COVID-19
Read article here.
Recent Publications
- Review in Current Opinion in Pharmacology of “Modulating regulatory T cell migration in the treatment of autoimmunity and autoinflammation” 7 May 2025
- Results of ARCADIA in Lancet (specifically eClinical Medicine journal which is part of Lancet)): A randomised, double-blind, placebo-controlled, multicentre clinical trial of AZD1656 in diabetic patients hospitalised with COVID-19 7 May 2025
- ARCADIA study protocol 7 May 2025